🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

AzurRx Bio's MS1819-SD shows treatment effect in mid-stage pancreatitis study; shares up

Published 09/27/2017, 10:02 AM
© Reuters.  AzurRx Bio's MS1819-SD shows treatment effect in mid-stage pancreatitis study; shares up
ENTO
-
  • Thinly traded nano cap AzurRx BioPharma (NASDAQ:AZRX) is up 9% on a 6x spike in volume, albeit on turnover of only 226K shares, in response to its announcement of positive results from an Australia-based Phase 2a clinical trial assessing MS1819-SD in pancreatitis patients with exocrine pancreatic insufficiency.
  • Both clinical activity and dose response were observed. The highest dose cohort experienced a 21% improvement in coefficient of fat absorption (CFA) in evaluable patients. The maximum response was 57%. Favorable trends were observed on other endpoints.
  • No significant safety signals were observed.
  • MS1819 is a recombinant lipase derived from the yeast Yarrowia Lipolytica.
  • The company is developing the product with Laboratoires Mayoly Spindler under which AzurRx owns exclusive rights for North America.
  • Now read: Ablynx - Catalyst Next Month, Good Midterm Buy


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.